Loading…
Pacific Biosciences of California Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in PACB.
▼ -93.9% over 5Y.
today you would have $63.41▼ -93.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 16 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.87 | $1.83 | $9.81 | $8.18 | $20.46 | $25.94 | $5.14 | $7.40 | $2.64 | $3.80 | $13.13 | $7.84 | $5.23 | $1.70 | $2.80 | $15.91 | |
| P/E | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PRLDPrelude Therapeutics Inc | $5.47 | — | 4.2x | — | -57.73% | $436.53M |
| CMPXCompass Therapeutics, Inc. | $2.40 | — | 2.6x | — | -56.66% | $432.21M |
| FENCFennec Pharmaceuticals Inc | $12.27 | — | 10.1x | — | -18.58% | $430.27M |
| EPRXEupraxia Pharmaceuticals Inc | $6.68 |
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Company description provided by Yahoo Finance.
| — |
| — |
| — |
| — |
| — |
| 152.6x |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| P/S | 10.9x | 3.5x | 3.5x | 13.1x | 15.8x | 34.7x | 63.5x | 8.7x | 14.2x | 3.7x | 3.9x | 12.1x | 9.6x | 13.1x | 3.8x | 4.6x | 502.3x |
| P/B | 4.7x | 105.6x | 1.1x | 3.7x | 3.6x | 5.7x | 14.9x | 14.3x | 9.8x | 4.0x | 4.2x | 15.3x | 10.6x | 5.3x | 0.9x | 0.8x | 3.0x |
| EPS | -$1.82 | -$1.59 | -$1.21 | -$1.40 | -$0.89 | $0.17 | -$0.55 | -$0.76 | -$0.87 | -$0.83 | -$0.42 | -$0.94 | -$1.26 | -$1.69 | -$2.03 | -$14.10 |
| Profit margin | -145.91% | -341.47% | -201.18% | -152.97% | -244.92% | -138.85% | 37.27% | -92.57% | -130.44% | -98.63% | -81.99% | -34.16% | -109.19% | -281.37% | -363.56% | -323.03% | -8373.12% |
| ROE | -73.76% | -10214.54% | -61.16% | -43.74% | -55.83% | -22.91% | 8.76% | -153.20% | -89.92% | -107.07% | -87.84% | -43.10% | -120.40% | -114.62% | -86.36% | -57.13% | -50.08% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 4.3x |
| — |
| -66.70% |
| $441.04M |
| BNTCBenitec Biopharma Inc. | $12.47 | — | 2.3x | — | -29.58% | $428.4M |
| BIOABioAge Labs, Inc. | $9.65 | — | 1.2x | — | -28.21% | $442.91M |